From the Phage Therapy Center (Tbilisi) Web site it is possible to find out the application range of Bacteriophage Therapy.
There is also a list of main Bacteria involved:
* Staphylococcus spp. (more than one species) including Methicillin Resistant Staphylococcus aureus (MRSA) and Community Associated Staphylococcus aureus (CA-MRSA).
* Streptococcus spp.
* Enterococcus spp.
* E. coli
* Proteus spp.
* Klebsiella pneumoniae ( before it was considered but now is out , why? because it is resistant?)
* Pseudomonas aeruginosa
* Several Other Bacterial Strains that are Emerging as Significant Challenges Even to the Most Advanced Antibiotics
* Infections Complicated with Candida and Other Yeast / Fungi
These Bacteria are involved in specific infections and in patological processes as:
-Chronic Infections
Antibiotics
fail to cure many chronic infections because they are due to biofilms.
Biofilms are complex mixtures of microbes that typically resist the
effects of antibiotics:
* Chronic and Acute Urinary Tract Infections (UTI) and Cystitis
* Ear Infections (Otitis Media)
* Chronic Sinusitis (Rhinosinusitis)
* Skin Infections
* Intestinal Infections
* Prostatitis and Associated Sexual Problems
-Infections Where Circulation is Poor
Poor
circulation makes it difficult to deliver the right concentration of
antibiotics to the infected area. Such conditions include, but are not
limited to, the following:
* Infected Wounds
* Osteomyelitis
* Diabetic Foot
* Tropic Ulcers
* Bed Sores
-Infections with Bacteria Resistant to Standard or Advanced Antibiotics
information
Whoever comes in this website may find a hint
Phage therapy is influenced by:
Phage therapy is influenced by:
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".
"In silico"
From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson
Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.